Lilly Asia Ventures returned for the respiratory disease drug developer's series B round, having co-led its $85m series A last year.

US-based immunotherapy developer Ansun Biopharma closed an $80m series B round yesterday that included Lilly Asia Ventures, a corporate venturing representative of pharmaceutical firm Eli Lilly. Investment manager Oceanpine Capital led the round, which was also backed by Yuanming Capital, Korea Investment Partners, Matrix Partners China, Lyfe Capital and, according to China Money Network, Junson…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.